Abstract: The present invention discloses compositions and methods for selectively delivering apoptosis inducing agents to the tumor prior to conventional therapeutic treatment protocol. Specifically, the present invention relates to an ensemble (or ‘AAAPT bioconjugate’) comprising an apoptogen (A) and a tumor targeting group (T), wherein the apoptogen is either connected directly to the targeting group or optionally attached through an intervening linker (L). The apoptogen may be a small or large molecule that activates apoptosis pathway and causes cell death. The targeting vector may be a small or large molecule that delivers the apoptogen selectively to the tumors. The linker may comprise simple alkylene chain or may contain functional groups that are capable of being cleaved by enzymatic process.

Abstract: The present invention relates to the AAAPT bioconjugate of general Formula 1 or 2, wherein A may be a small molecule such as, but is not limited to ?-tocopherol succinate (1), benzamide riboside (2), bortezomib (3), cycloheximide (4), or hispolone (5) or a macromolecule such as, but not limited to TRAIL, or AIF1 Flavoprotein. L is an alkylene or polyoxaalkyene chain selected from the group comprising —OC(CH2)aCO—, —HN(CH2)bCO—, —OC(CH2)cNH—, —HN(CH2)dNH—, —HN(CH2)e—, —O(CH2)f(CH2CH2O)g(CH2)hO—, —OC(CH2)i(CH2CH2O)j(CH2)kCO—, and —HN(CH2)i(CH2CH2O)j(CH2)kNH—. L may optionally contain acid enzymatically cleavable polypeptide sequences. T is selected from the group comprising somatostatin receptor binding agents, folate receptor binding agents, cathepsin B binding agents, matrix metalloprotein-2 (MMP-2) binding agents, GRP receptors, estrogen receptors, epidermal growth factor receptors (EGFR), and benzodiazepine.

Abstract: The present invention is directed to novel radiopharmaceuticals, which can be used to image myocardium. In addition, the present invention is directed to methods for risk stratification of patients who have suffered at least one myocardial infarction.